Core Insights - Absci Corporation is a clinical-stage biopharmaceutical company focused on drug discovery using generative AI and synthetic biology [1][5] - The company is participating in the 44th Annual J.P. Morgan Healthcare Conference, indicating its commitment to innovation in therapeutics [4][5] Stock Performance - H.C. Wainwright maintains a "Buy" rating for Absci, raising the price target from $7 to $8, with the stock currently trading at $3.53 [2][5] - The stock has fluctuated between $3.50 and $3.64 during the day, with a yearly high of $6.33 and a low of $2.01 [3][5] - Absci's market capitalization is approximately $531.3 million, with a trading volume of 1,367,859 shares today, indicating active investor interest [3]